A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer
Sponsor: Genentech, Inc.
Listed as NCT00262067, this PHASE3 trial focuses on Metastatic Breast Cancer and remains ongoing. Sponsored by Genentech, Inc., it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Acapulco, Mexico , Aguascalientes, Mexico , Amstelveen, Netherlands , Apeldoorn, Netherlands , Athens, Greece , Callao, Peru , Chania, Greece , Chelsmford, United Kingdom , Chelyabinsk, Russia and 74 more locations